YolTech Therapeutics Announces Successful Completion of Dose Escalation Phase in Phase I Trial of YOLT-201 for ATTR
SHANGHAI, Dec. 21, 2024 /PRNewswire/ -- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201, a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for ATTR amyloidosis. The trial has completed dosing in eight participants, including six patients with ATTR amyloidosis with polyneuropathy (ATTR-PN) and two patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM), across two...
Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards
Commercial validation in Europe parallels ongoing RESPONDER-HF clinical trial TEWKSBURY, Mass., Dec. 21, 2024 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure, announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745). The Corvia Atrial Shunt is...
United Imaging Intelligence at RSNA 2024: Empowering a More Intelligent and Connected World with Medical AI
CHICAGO, Dec. 20, 2024 /PRNewswire/ -- As RSNA 2024 concluded, United Imaging Intelligence (UII), a subsidiary of United Imaging Group specializing in medical AI, made a significant impression with a visionary showcase that seamlessly aligned with the event's theme: "Building Intelligent Connections." Revolutionizing Healthcare with Groundbreaking Foundation Model Applications At the core of UII's showcase was the...
Medicilon Appoints Dr. Lilly Xu as Chief Technology Officer
BOSTON, Dec. 20, 2024 /PRNewswire/ -- Medicilon, a leading preclinical contract research organization (CRO), has named Dr. Lilly Xu as its new Chief Technology Officer (CTO). With over 30 years of experience in preclinical drug development, Dr. Xu will lead Medicilon's technological innovation and global expansion, strengthening its capabilities to deliver cutting-edge R&D solutions. Dr. Lilly Xu...
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China’s National Medical Products Administration
SAN FRANCISCO and SUZHOU, China, Dec. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, today announced that China's National Medical Products Administration (NMPA) has approved a New Drug Application (NDA) of...
CNN explores the fascinating science of sweat – On Vital Signs
HONG KONG, Dec. 20, 2024 /PRNewswire/ -- With rapid advancements in sweat diagnostics, CNN's Chief Medical Correspondent, Dr. Sanjay Gupta, explores how one of the body's most overlooked fluids has the potential to transform healthcare on Vital Signs. From monitoring diseases to enhancing mental wellness and advancing precision medicine, sweat is emerging as...
VISTA Eye Specialist Redefines Healthcare Marketing in Malaysia with Groundbreaking “31 Days Challenge” Campaign
PETALING JAYA, Malaysia, Dec. 20, 2024 /PRNewswire/ -- Leading the way in advanced eye care and healthcare innovation, VISTA Eye Specialist ('VISTA') has set a new benchmark for digital healthcare marketing in Malaysia with its transformative "31 Days Challenge" campaign. Conducted in August and October 2024, the campaign strategically aligned with significant milestones such as Merdeka, the Paris Olympics,...
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation Announce $11M Investment to Advance PMB-CT01 (BAFF-R CAR T cell therapy) for Relapsed/Refractory Follicular Lymphoma
Based on promising early clinical results from PeproMene Bio's PMB-102 Phase 1 study, they will receive $6M USD upfront plus an additional $5M USD in conditional tranched investments from the Institute for Follicular Lymphoma Innovation. Patients with relapsed/refractory follicular lymphoma will be included in the expansion phase of PeproMene Bio's PMB-102 Phase...
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY Achieved gross profit of RMB 307.3 million, a growth of 39.1% YoY Gross margin increased to 82.6% from 80.9% in the same period of FY2024 Total operating expenses decreased to RMB 276.4 million, down 31.6% YoY Recorded net income of RMB 20.6 million, and adjusted net income (Non-GAAP)...
BGM Group and Jointown Deepen Cooperation, Ushering in a New Era of Pharmaceutical Development
CHENGDU, China, Dec. 19, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), Mr. Xin Zhanchang, Chairman of the Board of Directors of BGM Group and Chairman of Gansu Qilianshan Pharmaceutical Co., Ltd., led the sales team to visit their long-term strategic partner, Jointown Pharmaceutical Group. They were warmly welcomed by Mr. Liu Shulin, one of the...
